NXP 900
Alternative Names: eCF-506; NXP-900Latest Information Update: 08 May 2025
At a glance
- Originator University of Edinburgh
- Developer Nuvectis Pharma; University of Edinburgh
- Class Antineoplastics; Carbamates; Piperidines; Pyrazoles; Pyrimidines; Small molecules
- Mechanism of Action Proto-oncogene protein c-yes inhibitors; Src-family kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
- Preclinical Squamous cell cancer
Most Recent Events
- 29 Apr 2025 Pharmacodynamics and adverse events data from a phase Ia trial in Solid tumours released by Nuvectis Pharma
- 29 Apr 2025 Pharmacodynamics data from preclinical trial in Solid tumours released by Nuvectis Pharma
- 25 Apr 2025 Pharmacodynamics data from a preclinical trial in Solid tumours presented at the 116th Annual Meeting of the American Association for Cancer Research (AACR-2025)